Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

Next Previous
Trial Profile

Exploration of TNF-alpha Blockade With Golimumab in the Induction of Clinical Remission in Patients With Early Peripheral Spondyloarthritis (SpA) According to ASAS-criteria

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Golimumab (Primary) ; Methotrexate
  • Indications Axial spondyloarthritis; Spondylarthritis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms CRESPA

Most Recent Events

  • 06 Oct 2022 Results of post-hoc analysis assessing the reliability, validity, and sensitivity to change of a novel MRI scoring system in early peripheral spondylarthritis, published in the Rheumatology.
  • 20 Jan 2021 Results of CRESPA-Extension protocol (n=31) published in the Rheumatology
  • 28 Oct 2020 Results assessing axial involvement on MRI in early peripheral spondyloarthritis, published in the Annals of the Rheumatic Diseases

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top